PTSD Medical Cannabis UK: Treatment and Access

PTSD and Medical Cannabis in the UK

• PTSD is a recognised indication for medical cannabis prescribing by UK specialist doctors since 2018.
• The condition is one of the most common indications seen at UK private cannabis clinics.
• Both CBD-dominant and balanced THC:CBD products are used, depending on the severity of symptoms.
• UK prescribers typically work alongside psychological therapies rather than replacing them with cannabis.

Post-traumatic stress disorder affects veterans, emergency service workers, abuse survivors, and many others across the UK. Medical cannabis, prescribed legally by a specialist, has emerged as a meaningful adjunct to standard PTSD treatment for patients who have not responded adequately to SSRIs and trauma-focused therapy.

Evidence Base for Cannabis in PTSD

• Multiple observational studies report significant reductions in nightmare frequency, hypervigilance, and anxiety in PTSD patients using cannabis.
• The endocannabinoid system plays a direct role in fear extinction, the neurological process disrupted in PTSD.
• A 2021 Frontiers in Psychiatry review concluded that cannabinoids show promise as an adjunct PTSD treatment.
• Drug Science Project TWENTY21 included PTSD patients and found consistent improvements in quality of life outcomes.

The evidence base for cannabis in PTSD is growing rapidly, though definitive RCT data remains limited. UK specialist clinics are contributing to this evidence through structured patient follow-up and outcome tracking programmes.

Qualifying for a PTSD Cannabis Prescription in the UK

• A confirmed PTSD diagnosis from a psychiatrist, psychologist, or GP is required.
• Evidence of at least two failed treatment attempts — typically SSRIs and trauma-focused CBT — must be documented.
• Patients with a history of psychosis may not be eligible, as THC can increase psychosis risk in vulnerable individuals.
• Specialist assessment includes screening for comorbidities and any contraindications to cannabis treatment.

PTSD patients often present with complex comorbidities including depression, substance use, and chronic pain. UK cannabis specialists are experienced in managing these overlapping conditions and tailoring prescriptions accordingly.

Accessing Treatment and Costs

• Initial PTSD consultation at a UK private clinic: £150–£280.
• Monthly medication: £80–£200 for CBD-dominant products; £120–£250 for THC-containing prescriptions.
• NHS PTSD cannabis prescriptions are theoretically possible but rarely approved in practice.
• Veteran charities and trauma support organisations sometimes offer funding assistance for medical cannabis costs.

UK PTSD patients are strongly advised to use medical cannabis only within a supervised clinical framework. Self-medicating with unregulated cannabis carries risks that are particularly significant for those with trauma histories.